Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

Sponsor
Scholar Rock, Inc.
Study ID
NCT07435129
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • FSHD
  • Facioscapulohumeral Muscular Dystrophy

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Apitegromab — DRUG
    Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
  • Placebo — DRUG
    Placebo is administered every 4 weeks by intravenous (IV) infusion and does not contain the active ingredient.

Study Details

A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD

Key Dates

Start date
Aug 31, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apitegromab
    10 mg/kg IV
  • Placebo Comparator: Placebo
    Placebo IV

Primary Outcome Measure

Assess the efficacy of apitegromab compared with placebo in participants with FSHD [ Time Frame: 52 Weeks ]

Central Contacts

Related Studies